– USA, MA – Disc Medicine, Inc. (NASDAQ: IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced the appointment of Nadim Ahmed to its Board of Directors.
About Nadim Ahmed
Nadim Ahmed joins the Disc Medicine Board with more than twenty-five years of leadership experience across a range of development and commercialization roles. He is the President and CEO at Cullinan Therapeutics, a biopharmaceutical company developing a pipeline of clinical-stage programs focused on oncology and autoimmune diseases.
Before Cullinan Therapeutics, Nadim Ahmed worked at Bristol Myers Squibb, where he served as President, Hematology, and at Celgene Corporation, where he served as President, Global Hematology & Oncology. At Bristol Myers Squibb and Celgene, Nadim Ahmed oversaw multiple product launches and served as a member of both companies’ Leadership Teams.
Nadim Ahmed holds a Master of Science degree from Loughborough University, UK, and a Bachelor of Science degree from University College London, UK.
About Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis.
For more information: https://www.discmedicine.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.